Lyell Immunopharma (LYEL) Change in Account Payables (2020 - 2025)

Lyell Immunopharma (LYEL) has disclosed Change in Account Payables for 6 consecutive years, with $325000.0 as the latest value for Q4 2025.

  • Quarterly Change in Account Payables rose 115.96% to $325000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.3 million through Dec 2025, up 27.67% year-over-year, with the annual reading at -$2.3 million for FY2025, 27.67% up from the prior year.
  • Change in Account Payables hit $325000.0 in Q4 2025 for Lyell Immunopharma, up from -$779000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $2.9 million in Q1 2022 to a low of -$2.0 million in Q4 2024.
  • Historically, Change in Account Payables has averaged -$167550.0 across 5 years, with a median of -$172000.0 in 2024.
  • Biggest five-year swings in Change in Account Payables: soared 363.25% in 2022 and later crashed 6230.43% in 2023.
  • Year by year, Change in Account Payables stood at $99000.0 in 2021, then tumbled by 631.31% to -$526000.0 in 2022, then skyrocketed by 180.8% to $425000.0 in 2023, then plummeted by 579.06% to -$2.0 million in 2024, then soared by 115.96% to $325000.0 in 2025.
  • Business Quant data shows Change in Account Payables for LYEL at $325000.0 in Q4 2025, -$779000.0 in Q3 2025, and -$231000.0 in Q2 2025.